Vertex Pharmaceuticals Amortization of Right-of-Use Assets remained flat by 0.0% to $1.80M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 76.7%, from $7.73M to $1.80M. Over 2 years (FY 2023 to FY 2025), Amortization of Right-of-Use Assets shows a downward trend with a -58.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Changes reflect the scale of the company's leased asset base and the remaining duration of lease contracts.
The non-cash expense representing the systematic allocation of the cost of a right-of-use asset over its lease term. Thi...
Standard accounting metric for companies reporting under ASC 842.
tmusz_amortization_of_rou_assets| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $42.70M | $30.90M | $7.20M |
| YoY Change | — | -27.6% | -76.7% |